The core technology patent for Cellusion’s development product CLS001,
“Cell Seeding Agent And Material For Cell Transplantation” was granted in Japan

Cellusion Director and Executive Appointments

Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001

Announcement on Appointment of Officers

Cellusion has been selected for the AMED subsidy program

The core technology patent for Cellusion’s development product CLS001,
“METHOD FOR DERIVING CORNEAL ENDOTHELIUM REPLACEMENT CELLS FROM IPS CELLS” was granted in Japan

Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round

Announcement on Appointment of Officers

Dr. Jun Shimazaki, Professor Emeritus of Tokyo Dental College, Appointed as Scientific Advisor to Cellusion

Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)